Replies to post #219608 on Biotech Values

[DewDiligence]

Mavyret’s US new-patient share=50.5%—the highest ever—in week ending 7/13/18 (according to IMS).

In the same week, GILD’s NRx% fell to 48.2%, and MRK’s NRx% held steady at 1.4%.

Mavyret’s TRx% in the week ending 7/13/18 was 44.1%, also the highest-ever weekly figure.